Gene therapy data shake Solid
Better-looking safety might not be enough to get Solid back in the Duchenne muscular dystrophy game.
Gene therapy trial fails to rectify Sarepta’s sorry record
Sarepta’s first ever controlled study, of a Duchenne muscular dystrophy gene therapy, brings the markets down to earth.
A handful of huge gains stand out among mid and small-cap biotechs
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
Gene therapy clinical holds take centre stage
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
Wave takes a different tack from Sarepta in Duchenne
Wave will soon report key early-stage data with its exon-skipping DMD candidate suvodirsen but, unlike Sarepta, the group is starting its confirmatory trial before…
